Your session is about to expire
← Back to Search
Amlitelimab for Eczema (RIVER-AD Trial)
RIVER-AD Trial Summary
This trialwill study the safety and effectiveness of a drug in adults with moderate to severe AD, requiring visits every 4 weeks and if needed, home visits for administration of drug and assessment of vital signs.
RIVER-AD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRIVER-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RIVER-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no cancer history, except for non-melanoma skin cancer cured over 5 years ago.I am 18 years old or older.I have a skin condition that could interfere with skin tests.I have a history of serious infections or a weak immune system.I have fully recovered from side effects of previous Alzheimer's drugs for more than 2 weeks.I do not have severe illnesses like heart failure or kidney disease that would stop me from joining the study.I have had a solid organ or stem cell transplant.I do not have active or latent TB, nor have I been in close contact with TB patients recently.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Amlitelimab
Frequently Asked Questions
Are members of the public currently able to access this clinical experiment?
"Affirmative, the information hosted on clinicaltrials.gov displays that this study is presently enrolling patients. The medical trial was initially posted on August 22nd 2022 and has been recently revised as of November 29th 2022. 300 people are currently being sought from 3 different sites for participation in the research."
How many enrollees are being admitted to this research endeavor?
"Affirmative, clinicaltrials.gov states that this research project is currently engaging in recruitment efforts. It was posted on 8th August 2022 and modified most recently on 29th November 2022. It aims to source 300 participants from 3 different sites."
Has Amlitelimab been given regulatory authorization by the FDA?
"Our assessment at Power of Amlitelimab's safety is a 2 due to the lack of efficacy trials and only some data on its security."
Share this study with friends
Copy Link
Messenger